Compare Virgin Galactic Holdings, Inc. (SPCE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Zoetis Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $3.14 (market cap $499.54M), while Zoetis Inc trades at $75.76 (market cap $30.39B). The key difference: Zoetis Inc is far larger — about 60.8× Virgin Galactic Holdings, Inc.'s market cap, and Zoetis Inc pays a 2.88% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| SPCE | ZTS | |
|---|---|---|
Market Cap | $499.54M | $30.39B |
Sector | Industrials | Health |
52-Week High | $7.52 | $156.76 |
52-Week Low | $2.17 | $71.91 |
Enterprise Value | $463.52M | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.14, down 4.56% amid concerns over delayed commercial spaceflight operations to 2027 despite recent earnings beats. The stock shows technical bullish signals from moving averages but overbought RSI readings near 90. Fundamentally, the company continues to report significant losses with negative profit margins exceeding -19,000% and revenue of just $1.54 million in 2025, though cash flow trends show gradual improvement.
The outlook remains highly speculative with commercialization delays creating execution risk, while analyst sentiment is divided with 29% buy ratings. Key opportunities include potential space tourism market leadership, but risks include persistent cash burn, high debt levels, and intense competition in the emerging space sector.
Zoetis (ZTS) trades at $75.83, up 0.64% on the day, but near its 52-week low after recent pressure. The stock shows bearish technical signals with support at $71 and resistance at $76. Fundamentally, the company maintains strong profitability with a 27.69% net margin and 64.91% ROE, though Q2 2026 revenue missed estimates and full-year guidance was cut due to softer pet healthcare demand. Recent news includes an FDA emergency use authorization for a new treatment and a class action lawsuit deadline.
The outlook is mixed: valuation appears reasonable with a P/E of 12, and analyst consensus targets $94.90, implying upside. However, near-term headwinds from competitive pressures and legal risks warrant caution. Long-term investors may find value if execution improves, but volatility could persist amid demand challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
